Literature DB >> 30061951

Analysis of variants at LGALS3 single nucleotide polymorphism loci in skull base chordoma.

Kaibing Tian1,2,3,4, Liang Wang1,2,3,4, Ke Wang1,2,3,4, Junpeng Ma1,2,3,4, Da Li1,2,3,4, Yang Yang1,2,3,4, Guijun Jia1,2,3,4, Zhen Wu1,2,3,4, Liwei Zhang1,2,3,4, Junting Zhang1,2,3,4.   

Abstract

Although LGALS3 has been widely studied, the genotypes of the LGALS3 single nucleotide polymorphism (SNP) loci in skull base chordoma (SBC) have been not well defined. The aim of the current study was to analyze two LGALS3 SNP genotypes in patients with SBC. A total of 48 patients with SBC who underwent surgical treatment in Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University (Beijing, China) and 66 healthy participants were included in the present study. A total of two SNPs (LGALS3+191 C>A and LGALS3 +292 A>C) were selected for sequencing analysis of amplified target fragments from DNA that was extracted from blood samples. The clinical features of the patients were recorded, follow-up was conducted and statistical analysis was performed with SPSS 20.0. There were no differences in age and sex between the patients and control group. In addition, there were no significant differences in the distribution of genotypes (P=0.662) and allelic frequencies (P=0.638) at LGALS3+191 C>A between the two groups. However, significant difference was observed in the allelic distributions at LGALS3 +292 A>C between them (P=0.016), and allele A was associated with the occurrence of SBC. The distribution of the genotypes at LGALS3 +292 A>C was not significantly different in the additive model (CC vs. AC vs. AA, P=0.083) but was significantly different in the dominant model (CC+AC vs. AA, P=0.043). In the Kaplan-Meier analysis, there were no significant differences in the overall survival and progression analysis between different genotypes at LGALS3 +191 C>A (P=0.168 and P=0.120) in patients with SBC. There was no significant difference in overall survival was observed between the genotypes at +292 A>C (P=0.595). However, the progression-free survival (PFS) time of the CC+AC genotype group was longer compared with the AA genotype group (P<0.001). In the univariate and multivariate analysis of tumor progression, PFS was shorter in the AA genotype group compared with the CC+AC genotype group (P<0.001). The allele A and AA genotype at LGALS3 +292 A>C were observed to be associated with a higher risk of SBC, and the AA genotype at +292 A>C was associated with a shorter PFS time.

Entities:  

Keywords:  chordoma; galectin-3; gene; skull base

Year:  2018        PMID: 30061951      PMCID: PMC6063035          DOI: 10.3892/ol.2018.8780

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  44 in total

1.  Chordoma: incidence and survival patterns in the United States, 1973-1995.

Authors:  M L McMaster; A M Goldstein; C M Bromley; N Ishibe; D M Parry
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

Review 2.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

3.  Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.

Authors:  Natsuo Oka; Susumu Nakahara; Yukinori Takenaka; Tomoharu Fukumori; Victor Hogan; Hiro-Omi Kanayama; Takashi Yanagawa; Avraham Raz
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

4.  Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas.

Authors:  Fortios Tzortzidis; Foad Elahi; Donald Wright; Sabareesh K Natarajan; Laligam N Sekhar
Journal:  Neurosurgery       Date:  2006-08       Impact factor: 4.654

5.  Clinical and pathological features of intradural retroclival chordoma.

Authors:  Liang Wang; Zhen Wu; Kaibing Tian; Guilin Li; Junting Zhang
Journal:  World Neurosurg       Date:  2013-02-13       Impact factor: 2.104

6.  Detection and distribution of the carbohydrate binding protein galectin-3 in human notochord, intervertebral disc and chordoma.

Authors:  W Götz; M Kasper; N Miosge; R C Hughes
Journal:  Differentiation       Date:  1997-12       Impact factor: 3.880

7.  Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3.

Authors:  Jun Shen; Chao-Ding Li; Hui-Lin Yang; Jian Lu; Tian-Ming Zou; Dong-Lai Wang; Min Deng
Journal:  J Clin Neurosci       Date:  2010-09-19       Impact factor: 1.961

8.  Skull base chordomas: correlation of tumour doubling time with age, mitosis and Ki67 proliferation index.

Authors:  J L Holton; T Steel; M Luxsuwong; H A Crockard; T Revesz
Journal:  Neuropathol Appl Neurobiol       Date:  2000-12       Impact factor: 8.090

9.  Chordoma: role of radiation therapy.

Authors:  B E Amendola; M A Amendola; E Oliver; K D McClatchey
Journal:  Radiology       Date:  1986-03       Impact factor: 11.105

10.  Ecchordosis physaliphora and chordoma: a comparative ultrastructural study.

Authors:  K L Ho
Journal:  Clin Neuropathol       Date:  1985 Mar-Apr       Impact factor: 1.368

View more
  1 in total

1.  Altered expression of genes related to innate antifungal immunity in the absence of galectin-3.

Authors:  Caroline Patini Rezende; Patricia Kellen Martins Oliveira Brito; Andre Moreira Pessoni; Thiago Aparecido Da Silva; Gustavo H Goldman; Fausto Almeida
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.